According to IP Holdings, the IP, which centers on the XPNPEP2 gene, "pertains to extensive segments of the human genome sequence and its applications to microarray manufacturing, gene testing and development of therapeutic agents."
The gene codes for the protein membrane-bound aminopeptidase P (AmP). The gene has received a US Patent, No. 6,399,349, entitled "Human Aminopeptidase P Gene."
IP Holdings claims the gene is a marker for hypertension, angioedema, rejection of kidney transplants, and certain tumors. The patent covers cDNA and gDNA sequences coding AmP; a method of producing AmP; the diagnostics for detecting AmP abnormalities; and prevention and treatment of medical conditions associated with the mutation of the AmP gene, IP Holdings said.
"We plan to pursue a comprehensive licensing program to ensure the broad proliferation of Ryogen's IP," said Alexander Poltorak, managing director of IP Holdings.
Ryogen is exploring a number of alternatives to license the AmP patent, including "ways to make this gene widely available for research so as to promote the development of genetic testing and treatment.